1-9 of 9
David Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells

Veronica Calvo, Wei Zheng, Anna Adam-Artigues, Kirk A. Staschke, Xin Huang, Julie F. Cheung, Ana Rita Nobre, Sho Fujisawa, David Liu, Maria Fumagalli, David Surguladze, Michael E. Stokes, Ari Nowacek, Mark Mulvihill, Eduardo F. Farias, Julio A. Aguirre-Ghiso
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5155–5172.
https://doi.org/10.1158/1078-0432.CCR-23-1427
Published: 15 December 2023
View article titled, A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
Open the PDF for A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer

Judit Börcsök, Zsofia Sztupinszki, Raie Bekele, Sizhi P. Gao, Miklos Diossy, Amruta S. Samant, Kasia M. Dillon, Viktoria Tisza, Sándor Spisák, Orsolya Rusz, Istvan Csabai, Helle Pappot, Zoë J. Frazier, David J. Konieczkowski, David Liu, Naresh Vasani, James A. Rodrigues, David B. Solit, Jean H. Hoffman-Censits, Elizabeth R. Plimack, Jonathan E. Rosenberg, Jean-Bernard Lazaro, Mary-Ellen Taplin, Gopa Iyer, Søren Brunak, Rita Lozsa, Eliezer M. Van Allen, Dávid Szüts, Kent W. Mouw, Zoltan Szallasi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 2011–2022.
https://doi.org/10.1158/1078-0432.CCR-20-3316
Published: 01 April 2021
View article titled, Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer
Open the PDF for Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B29: Use of deep sequencing of urinary DNA as a biomarker of residual disease status at the time of radical cystectomy

Phillip H. Abbosh, Uttam Satyal, David Liu, Ilsiya Ibragimova, Lauren Szeto, Benjamin Miron, James Ford, Daniel Parker, Aeen Asgar, Daniel M. Geynisman, R. Katherine Alpaugh, Paul Cairns, Costas D. Lallas, Edouard J. Trabulsi, Jean Hoffman-Censits, Eliezer M. Van Allen, Alexander Kutikov, Elizabeth R. Plimack
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15_Supplement): B29.
https://doi.org/10.1158/1557-3265.BLADDER19-B29
Published: 03 August 2020
View article titled, Abstract B29: Use of deep sequencing of urinary DNA as a biomarker of residual disease status at the time of radical cystectomy
Journal Articles

T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer

Aleksandar Z. Obradovic, Matthew C. Dallos, Marianna L. Zahurak, Alan W. Partin, Edward M. Schaeffer, Ashley E. Ross, Mohamad E. Allaf, Thomas R. Nirschl, David Liu, Carolyn G. Chapman, Tanya O'Neal, Haiyi Cao, Jennifer N. Durham, Gunes Guner, Javier A. Baena-Del Valle, Onur Ertunc, Angelo M. De Marzo, Emmanuel S. Antonarakis, Charles G. Drake
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3182–3192.
https://doi.org/10.1158/1078-0432.CCR-19-3372
Published: 01 July 2020
View article titled, T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Open the PDF for T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract NT-113: SC-003, AN ANTIBODY-DRUG CONJUGATE TARGETING DIPEPTIDASE 3, EXHIBITS POTENT ANTI-TUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF HIGH GRADE SEROUS OVARIAN CANCER

Wolf R. Wiedemeyer, Sheila Bheddah, Christine Saechao, Dorothy French, Erik Huntzicker, Aaron Kempema, Julia Gavrilyuk, David Liu, Vikram Sisodiya, Alina He, Zhaomei Zhang, Monette A. Aujay, Kristyn Hayashi, Sandro Vivona, Xi Zhao, Kimberly Walter, Laura R. Saunders, Johannes Hampl, Shravanthi Madhavan, Marybeth Pysz, Alexander J. Bankovich, Holger Karsunky, Scott J. Dylla
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): NT-113.
https://doi.org/10.1158/1557-3265.OVCASYMP18-NT-113
Published: 15 November 2019
View article titled, Abstract NT-113: SC-003, AN ANTIBODY-DRUG CONJUGATE TARGETING DIPEPTIDASE 3, EXHIBITS POTENT ANTI-TUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF HIGH GRADE SEROUS OVARIAN CANCER
Journal Articles

Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer

Sophia C. Kamran, Jochen K. Lennerz, Claire A. Margolis, David Liu, Brendan Reardon, Stephanie A. Wankowicz, Emily E. Van Seventer, Adam Tracy, Jennifer Y. Wo, Scott L. Carter, Henning Willers, Ryan B. Corcoran, Theodore S. Hong, Eliezer M. Van Allen
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5561–5571.
https://doi.org/10.1158/1078-0432.CCR-19-0908
Published: 13 September 2019
View article titled, Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer
Open the PDF for Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer in another window
Includes: Supplementary data
Journal Articles

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

Qiang Li, Alexis W. Damish, Zoë Frazier, David Liu, Elizaveta Reznichenko, Atanas Kamburov, Andrew Bell, Huiyong Zhao, Emmet J. Jordan, S. Paul Gao, Jennifer Ma, Philip H. Abbosh, Joaquim Bellmunt, Elizabeth R. Plimack, Jean-Bernard Lazaro, David B. Solit, Dean Bajorin, Jonathan E. Rosenberg, Alan D. D'Andrea, Nadeem Riaz, Eliezer M. Van Allen, Gopa Iyer, Kent W. Mouw
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 977–988.
https://doi.org/10.1158/1078-0432.CCR-18-1001
Published: 01 February 2019
View article titled, <em>ERCC2</em> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Open the PDF for <em>ERCC2</em> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B14: Neoantigen burden associates with chemoresponse in muscle-invasive bladder cancer patients receiving neoadjuvant chemotherapy

Philip H. Abbosh, David Liu, Michael H. Johnson, Wafik S. El-Deiry, Elizabeth R. Plimack, Jonathan E. Rosenberg, Eliezer M. Van Allen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1_Supplement): B14.
https://doi.org/10.1158/1557-3265.PMCCAVULN16-B14
Published: 02 January 2017
View article titled, Abstract B14: Neoantigen burden associates with chemoresponse in muscle-invasive bladder cancer patients receiving neoadjuvant chemotherapy
Journal Articles

Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer

Christine E. Horak, Lajos Pusztai, Guan Xing, Ovidiu C. Trifan, Cristina Saura, Ling-Ming Tseng, Stephen Chan, Rosanne Welcher, David Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1587–1595.
https://doi.org/10.1158/1078-0432.CCR-12-1359
Published: 14 March 2013
View article titled, Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Open the PDF for Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer in another window
Includes: Supplementary data